The Lupin Coral Springs manufacturing facility project is a planned 70,000 square foot pharmaceutical production plant in Broward County, Florida, carrying a $250 million investment by Mumbai-based Lupin Ltd. over five years. Development sources have since placed an occupancy target of approximately October 1, 2027 on the project, giving the programme a firmer near-term milestone than the broader 2030 job creation figure stated at announcement. No groundbreaking date has been publicly confirmed as of mid-2026, placing the facility in active pre-construction and permitting.
Construction Jobs Figure and Florida’s Pharma Standing Add Weight to the Project
A figure not included in the original announcement has since been confirmed by the Association for Accessible Medicines: beyond the 200 permanent positions, the build phase is expected to generate over 1,000 construction jobs in Broward County. The project sits within a Florida market that has risen to second in the nation for both pharmaceutical and medical device manufacturing, giving Lupin a structurally strong operating environment. A parallel dynamic is visible further north: Hikma Pharmaceuticals’ $267 million expansion across Bedford and Columbus, Ohio follows the same domestic onshoring logic, with Ohio and Florida now competing as the country’s two most active nodes for generic medicine manufacturing investment.
Project Overview
- Project Name: Lupin Coral Springs Pharmaceutical Manufacturing Facility
- Location: Coral Springs, Broward County, Florida, USA
- Developer / Owner: Lupin Limited (BSE: 500257 / NSE: LUPIN), Mumbai, India; U.S. headquarters in Naples, Florida
- Total Cost / Value: $250 million cumulative over five years, covering R&D, infrastructure, and capital expenditure
- Scale / Capacity: 70,000 sq ft on more than 5 acres; capacity for 25+ critical respiratory medicines including albuterol inhalers
- Construction Start: Not yet confirmed; site acquired, project in pre-construction and permitting phase as of mid-2026
- Expected Completion: Occupancy targeted at approximately October 1, 2027; full job creation target by 2030
- Funding / Financing: Corporate funding supplemented by Florida state tax credits and incentives
- Current Status: Pre-construction; incentive agreements in place, groundbreaking not yet announced
- Key Milestone: Over 1,000 construction jobs projected during the build phase, in addition to 200+ permanent skilled roles
Project Team
- Lupin Limited — Client / Developer / Owner
- FloridaCommerce / Select Florida — State Economic Development Partner
- City of Coral Springs — Local Government Partner
- Greater Fort Lauderdale Alliance — Regional Economic Development Partner
- Broward County Commission — County Government and Incentive Partner
- Unnamed Workforce and College Partner — Talent Pipeline and Training Support
- Main Contractor — Not yet awarded
- Design / Engineering Firm — Not yet disclosed
Reported 8th October 2025: Lupin Ltd. plans to invest $250 million over five years to build a pharmaceutical manufacturing facility in Coral Springs, Florida, as part of its strategy to expand U.S.-based production of respiratory medicines.
The Mumbai-based company said the planned 70,000-square-foot facility, located on more than five acres, will be capable of producing over 25 respiratory treatments, including albuterol inhalers for asthma patients and military personnel. The investment covers research and development, infrastructure, and capital expenditures.
Lupin said the project will help diversify supply chains, strengthen domestic manufacturing, and enhance the nation’s medicine security. The company expects to create more than 200 skilled jobs in Broward County by 2030.
“The new facility will build on Lupin’s existing presence in Florida, home to our headquarters and Advanced Inhalation Research Center,” said Christoph Funke, the company’s Chief Technical Operations Officer. “This investment underscores our commitment to innovation, quality and reliable supply, and reflects our collaboration with Florida’s leaders to strengthen U.S. medicine security.”
Florida’s Secretary of Commerce J. Alex Kelly welcomed the move, saying Lupin’s expansion reinforces the state’s growing role in life sciences and advanced manufacturing. “With strong research capacity, education programs and a leading talent pipeline, Florida has become a top destination for pharmaceutical investment,” Kelly said.
Partners, tax credits and incentives
Lupin has acquired the site for the project and will receive tax credits and incentives in recognition of its investment and job creation plans. The company is partnering with FloridaCommerce/Select Florida, the City of Coral Springs, the Greater Fort Lauderdale Alliance, and the Broward County Commission, along with an unnamed workforce and college partner.
Once complete, the Coral Springs plant will anchor Lupin’s U.S. respiratory operations and serve as a key production site for critical inhalation therapies.
The plan follows similar large-scale manufacturing investments by AbbVie, which broke ground on a $195 million API facility in North Chicago, Illinois, and Eli Lilly, which is developing a $6.5 billion API site in Houston, Texas. It also mirrors AstraZeneca’s $4.5 billion investment in Albemarle County, Virginia, as global drugmakers expand U.S. production capacity and reinforce domestic pharmaceutical supply chains.
Lupin Coral Springs Manufacturing Facility: Project Factsheet
Project overview
Company: Lupin
Project: New state-of-the-art pharmaceutical manufacturing plant
Location: Coral Springs, Broward County, Florida
Investment details
Total investment: $250 million (cumulative over five-year period)
Facility specifications
Land: More than 5 acres acquired
Size: 70,000 square feet expansion
Production capacity:
Capacity to accommodate production of more than 25 critical respiratory medicines
Includes lifesaving albuterol inhalers for children with asthma and service members at home and overseas
Economic impact
Job creation: Over 200 new long-term, skilled jobs by 2030 in Broward County
Existing presence:
Lupin’s headquarters located in Florida
Advanced Inhalation Research Center in Florida
Strategic objectives
Strengthen domestic manufacturing
Enhance supply chain diversification
Enhance medicine security
Strengthen Lupin’s position as a global respiratory leader
Anchor U.S. production of critical respiratory therapies
Diversify the supply chain
Ensure affordable, reliable access from routine pediatric care to pandemic-scale demand
Government support and partnerships
Incentives: Tax credits and incentives from the state of Florida
Project partners:
Florida Commerce/Select Florida
City of Coral Springs
Greater Fort Lauderdale Alliance
Broward County Commission
Workforce/college partner
Leave a Reply